Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone

Item Type:Article
Title:Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone
Creators Name:Luedtke, A. and Heck, K. and Genschel, J. and Mehnert, H. and Spuler, S. and Worman, H.J. and Schmidt, H.H.
Abstract:Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in LMNA, the gene that encodes nuclear lamins A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat. We present our 2 years' experience of treatment with rosiglitazone in a subject with FPLD. Insulin requirement decreased significantly from 240 IU/day to 76 IU/day (range 20-240 IU/day) and serum triglyceride concentration was lowered from 13.7 +/- 14.4 mmol/l to 4.5 +/- 4.3 mmol/l and remained stable. Mean HbA(1c) prior to rosiglitazone therapy was 9.4 +/- 1.32% and decreased to 7.4 +/- 0.6% during therapy with rosiglitazone. This case demonstrates the benefits of PPARgamma-agonists on glycaemic control and dyslipidaemia in a patient with FPLD. This in turn implies that PPARgamma may play a pathophysiological role in FPLD.
Keywords:Diabetes, Familial Partial Lipodystrophy, Hyperlipidaemia, Insulin Resistance, Thiazolidinedione
Source:Diabetic Medicine
ISSN:0742-3071
Publisher:Wiley-Blackwell (U.S.A.)
Volume:22
Number:11
Page Range:1611-1613
Date:November 2005
Official Publication:https://doi.org/10.1111/j.1464-5491.2005.01757.x
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library